---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-23-000079"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T08:51:39.997719+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q3 revenue up 50% to $180.6M; GAAP EPS $0.91, adj. $1.15

## Summary
- Net revenues of $180.6M for Q3 2023, up from $120.1M in Q3 2022 (50% increase).
- GAAP net income $49.2M ($0.91 diluted EPS) vs $15.9M ($0.30) a year ago.
- Adjusted non-GAAP net income $61.9M ($1.15 diluted EPS) vs $20.2M ($0.38).
- CEO attributes growth to diabetes portfolio, including BAQSIMI acquisition and generic glucagon.
- Nine-month net revenues $466.3M vs $364.0M; GAAP net income $101.4M vs $57.5M.

## SEC filing metadata
- accession: 0001297184-23-000079
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000079/0001297184-23-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000079/amph-20231108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-23-000079
- JSON: https://secwatch.observer/filing/0001297184-23-000079.json
- Plain text: https://secwatch.observer/filing/0001297184-23-000079.txt

## Key facts
- Earnings Releases
  Amphastar Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: revenue $180.6 million, net income $49.2 million, or $0.91 per share, EPS $0.91 per share.
  - Period: three months ended September 30, 2023
  - Revenue: $180.6 million
  - Net income: $49.2 million, or $0.91 per share
  - EPS: $0.91 per share
  - Result: reported results
  source text: in such a filing. ​ --- EX-99.1 (EX-99.1) --- ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 23 ​ Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023 ​ RANCHO CUCAMONGA, CA – November 8, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000079/0001297184-23-000079-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.